HOME >> BIOLOGY >> NEWS
Amgen's decision to block reinstatement of GDNF is faulted by a leading Parkinson's advocacy group

effects of Parkinson's disease. Since the trial was halted last summer, many of these people, supported by organizations and thousands of well-wishers from around the Parkinson's community, have pleaded with Amgen to reinstate those subjects who wish to continue with the treatment and are willing to be carefully followed to generate ongoing data. We understand and fully accept that such reinstatement of treatment should take place only with appropriate waivers that would hold the company harmless in event of any complications, whether foreseen or unforeseen, and with the approval of the relevant Institutional Review Boards."

"The safety issues of neutralizing antibodies (found in some of the human subjects) and of cerebellar degeneration involving high-dosage GDNF (in some non-human primate subjects) need to be investigated and understood. If subjects are willing to offer themselves for continuing GDNF infusion with all of these safety concerns fully explained and understood by the subjects, then the Parkinson community science as well as patients can gain much new information related to the safety of GDNF infusions."

"In summary, the decision is a mistake because it denies the patients and their doctors the opportunity to continue with a potentially useful, albeit yet unproven, treatment, and it denies us all the opportunity to gather more scientific data about the long-term effects of GDNF. We hope very much that this company, which has long held a position of high respect in the business and health communities, will consider reversing its decision, and soon. In the meantime, the coalition of patient-voluntary groups which besides PDF includes the Parkinson's Action Network and the Parkinson's Pipeline Project -- will continue fighting for patients' interests as long as it takes."


'"/>

Contact: Christiana Evers
cevers@pdf.org
Parkinson's Disease Foundation
11-Feb-2005


Page: 1 2

Related biology news :

1. A nurse makes the decision on who will live
2. Cells use noise to make cell-fate decisions
3. Group decisions: From compromise to leadership in pigeon homing
4. AIUM supports FDA decision to deny over-the-counter use of handheld doppler fetoscopes
5. Titans of biodiversity science call for united, authoritative voice to inform decision-makers
6. Dover intelligent design decision to be topic of national forum
7. Honeybee decision-making ability rivals any department committee
8. Even at small scales, the big decisions are made at the water cooler
9. Amid growing public concerns, bioscience firms begin formalizing ethical decision-making practices
10. Ethical decision-making at bioscience companies
11. Dover decision is good for long-term economic and scientific strength

Post Your Comments:
(Date:8/22/2014)... , August 22, 2014 /PRNewswire/ ... http://www.researchandmarkets.com/research/mtm27l/biometrics_market ) has announced the addition ... America 2014-2018"  report to their offering.  ... , ,Biometrics is a technology that ... based on their physical or behavioral ...
(Date:8/22/2014)... a leading source of information for businesses and professionals, ... Riverside in its 2014 list of "some of the ... generate the list, the company analyzed citation data over ... has had enormous impact. , The following UC Riverside ... the greatest number of highly cited papers in one ...
(Date:8/22/2014)... Jolla, CA Research presented at the 29th ... being developed by Hera Therapeutics Inc. combats three ... cause 70 percent of all cervical cancer. , ... HTI-1968 blocked the replication of HPV-16, HPV-18 and ... and Thomas Broker, Ph.D., who presented the findings ...
Breaking Biology News(10 mins):Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 2Biometrics Market in North America 2014-2018: Key Vendors are 3M Cogent, Cross Match, NEC and Safran SA 35 UC Riverside scientists among world's most influential scientific minds 2
(Date:8/23/2014)... Virginia (PRWEB) August 23, 2014 ... NDA Partners LLC announced today that Janet B. ... Premier Expert consultant. NDA Partners Premier Experts are ... enable them to bring extraordinary value to the ... implement critical solutions to help clients successfully develop ...
(Date:8/22/2014)... Texas (PRWEB) August 23, 2014 ... the current state of the Papain industry in ... overview of the industry, including definitions, applications and ... domestic market analysis are provided with a focus ... the market. A comparison between the international and ...
(Date:8/22/2014)... 2014 Today the Academy of Model Aeronautics ... Court of Appeals for the D.C. Circuit challenging the FAA’s ... the Federal Register on June 25, 2014. , The ... the text and intent of the FAA Modernization and Reform ... prohibition on any new rules or regulations regarding model aircraft ...
(Date:8/22/2014)... (TSXV: BRM) ("Biorem" or "the Company") today announced results for the three ... second quarter financial statements and MD&A have been filed on SEDAR ( ... Six-months ended June 30, ( in CDN$,000 except per share ... 2014 , 2013 Revenue , 2,459 , ... 56 , 1,485 , 385 , ...
Breaking Biology Technology:Noted Epidemiologist and Former FDA Deputy Director Janet B. Arrowsmith, MD, Joins NDA Partners as a Premier Expert Consultant 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 2Papain Industry Global & China Development Trend and Proposals Analysis Research Report Available at DeepResearchReports.com 3AMA Files Petition for Review of FAA’s Interpretive Rule 2Biorem Reports 2014 Second Quarter Results 2Biorem Reports 2014 Second Quarter Results 3
Cached News: